Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis

Critical Care Medicine

Volumn 39, Issue 12, 2011, Pages 2678-2683

  Changsirivathanathamrong, Dechaboon ^a,b   Wang, Yutang ^a   Rajbhandari, Dorrilyn ^b   Maghzal, Ghassan J ^a   Mak, Wendy M ^a   Woolfe, Clive ^b   Duflou, Johan ^c   Gebski, Val ^a   Dos Remedios, Cris G ^a   Celermajer, David S ^b   Stocker, Roland ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Department of Forensic Medicine Sydney ^*  (Australia)

Author keywords

blood pressure; indoleamine 2,3 dioxygenase; inflammation; septic shock; tryptophan; vasodilation

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INOTROPIC AGENT; KYNURENINE; NORADRENALIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTENSION; INTENSIVE CARE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RESISTANCE BLOOD VESSEL; SEPTIC SHOCK; TRYPTOPHAN METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPOTENSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; MALE; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TRYPTOPHAN; YOUNG ADULT;

EID: 81855221935     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822827f2     Document Type: Article

References (27)

1. Annane D, Aegerter P, Jars-Guincestre MC, et al: Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172 (Pubitemid 36920969)
2. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
3. Angus DC, Birmingham MC, Balk RA, et al: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723-1730 (Pubitemid 30196213)
4. Lukaszewicz AC, Payen D: The future is predetermined in severe sepsis, so what are the implications? Crit Care Med 2010; 38: S512-S517
5. Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010;36: 222-231
6. Gomez-Jimenez J, Salgado A, Mourelle M, et al: L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 1995; 23:253-258
7. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30 (Pubitemid 38125559)
8. Yamamoto S, Hayaishi O: Tryptophan pyrrolase of rabbit intestine. D-and L-tryptophancleaving enzyme or enzymes. J Biol Chem 1967; 242:5260-5266
9. Zeden JP, Fusch G, Holtfreter B, et al: Excessive tryptophan catabolism along the kynurenine pathway precedes ongoing sepsis in critically ill patients. Anaesth Intensive Care 2010; 38:307-316
10. Thomas SR, Stocker R: Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999; 4:199-220 (Pubitemid 30088218)
11. Wang Y, Liu H, McKenzie G, et al: Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16:279-285
12. Jung ID, Lee MG, Chang JH, et al: Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J Immunol 2009; 182: 3146-3154
13. Huttunen R, Syrjänen J, Aittoniemi J, et al: High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2010; 33:149-154
14. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
15. Thomas SR, Mohr D, Stocker R: Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-primed mononuclear phagocytes. J Biol Chem 1994; 269:14457-14464
16. Ferrari R, Fox K: Insight into the mode of action of ACE inhibition in coronary artery disease: The ultimate 'EUROPA' story. Drugs 2009; 69:265-277
17. Schofield WN: Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 1985; 39:S5-S41
18. Barak N, Wall-Alonso E, Sitrin MD: Evaluation of stress factors and body weight adjustments currently used to estimate energy expenditure in hospitalized patients. J Parenter Enteral Nutr 2002; 26:231-238 (Pubitemid 34680565)
19. Maghzal GJ, Thomas SR, Hunt NH, et al: Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. J Biol Chem 2008; 283:12014-12025
20. Kleinbaum D, Klein M: Logistic Regression: A Self Learning Text. Second Edition. New York, Springer, 2002
21. ARISE; ANZICS APD Management Committee: The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc 2007; 9:8-18
22. Takikawa O: Biochemical and medical aspects of the indoleamine 2,3-dioxygenaseinitiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005; 338:12-19 (Pubitemid 41540531)
23. Wolf AM, Wolf D, Rumpold H, et al: Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004; 113:47-55 (Pubitemid 39468267)
24. Schroecksnadel K, Winkler C, Duftner C, et al: Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 2006; 25:334-337
25. Wirleitner B, Rudzite V, Neurauter G, et al: Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33:550-554 (Pubitemid 36783213)
26. Stasch JP, Schmidt PM, Nedvetsky PI, et al: Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006; 116: 2552-2561 (Pubitemid 44330154)
27. Boruchow IB, Ludwig GD, Wontorsky D: Potentiation of endotoxin shock by oral L-tryptophan. Am J Physiol 1968; 214:525-531